1. Academic Validation
  2. Development of a Time-Resolved Fluorescence Resonance Energy Transfer Ultrahigh-Throughput Screening Assay for Targeting the NSD3 and MYC Interaction

Development of a Time-Resolved Fluorescence Resonance Energy Transfer Ultrahigh-Throughput Screening Assay for Targeting the NSD3 and MYC Interaction

  • Assay Drug Dev Technol. 2018 Feb/Mar;16(2):96-106. doi: 10.1089/adt.2017.835.
Jinglin Xiong 1 2 3 Valentina Gonzalez Pecchi 1 2 Min Qui 1 2 Andrey A Ivanov 1 2 Xiulei Mo 1 2 Qiankun Niu 1 2 Xiang Chen 3 Haian Fu 1 2 Yuhong Du 1 2
Affiliations

Affiliations

  • 1 1 Department of Pharmacology, Emory University School of Medicine , Atlanta, Georgia .
  • 2 2 Emory Chemical Biology Discovery Center, Emory University School of Medicine , Atlanta, Georgia .
  • 3 3 Department of Dermatology, Xiangya Hospital, Central South University , Changsha, China .
Abstract

Epigenetic modulators play critical roles in reprogramming of cellular functions, emerging as a new class of promising therapeutic targets. Nuclear receptor binding SET domain protein 3 (NSD3) is a member of the lysine methyltransferase family. Interestingly, the short isoform of NSD3 without the methyltransferase fragment, NSD3S, exhibits oncogenic activity in a wide range of cancers. We recently showed that NSD3S interacts with MYC, a central regulator of tumorigenesis, suggesting a mechanism by which NSD3S regulates cell proliferation through engaging MYC. Thus, small molecule inhibitors of the NSD3S/MYC interaction will be valuable tools for understanding the function of NSD3 in tumorigenesis for potential Cancer therapeutic discovery. Here we report the development of a cell lysate-based time-resolved fluorescence resonance energy transfer (TR-FRET) assay in an ultrahigh-throughput screening (uHTS) format to monitor the interaction of NSD3S with MYC. In our TR-FRET assay, anti-Flag-terbium and anti-glutathione S-transferase (GST)-d2, a paired fluorophores, were used to indirectly label Flag-tagged NSD3 and GST-MYC in HEK293T cell lysates. This TR-FRET assay is robust in a 1,536-well uHTS format, with signal-to-background >8 and a Z' factor >0.7. A pilot screening with the Spectrum library of 2,000 compounds identified several positive hits. One positive compound was confirmed to disrupt the NSD3/MYC interaction in an orthogonal protein-protein interaction assay. Thus, our optimized uHTS assay could be applied to future scaling up of a screening campaign to identify small molecule inhibitors targeting the NSD3/MYC interaction.

Keywords

MYC; NSD3; TR-FRET; epigenetics; protein–protein interaction; screening.

Figures
Products